Viral Vector and Plasmid DNA Manufacturing Market Size, Growth Opportunities, Revenue Share Analysis, and Forecast To 2028

The rise in prevalence of cancer, inherited disorders, viral infections, Alzheimer's, Parkinson's, rheumatoid arthritis are the major growth factors for viral vector and plasmid DNA manufacturing market. Besides, the growing number of gene modified therapies like Yescarta and Kymriah are also fueling the market growth.

According to the current analysis of Reports and Data, the global Viral Vector and Plasmid DNA manufacturing market is expected to reach USD 4.70 billion by the year 2028, with a CAGR of 23.8% during the forecast period. Viral and non-viral vectors have emerged as an efficient delivery mechanism for the development of innovative medicines. Viral vectors and plasmid DNA are products of gene therapy, which are used for the treatment of a large number of diseases such as cancer and other chronic disorders. The advantages of gene vaccines and gene therapy over conventional vaccines and therapies include the ability to induce a wide range of immune response types. The major driving factors that are boosting the growth of Viral Vector and Plasmid DNA manufacturing market are the global rise in the incidence of cancer, increase in geriatric population susceptible to diseases, government initiatives & grants and the increase in investment by private companies on R&D activities of viral vectors and plasmid DNA manufacturing.

Viral vectors and plasmid DNA can reduce the cost of treatment and help to decrease the repeated administration of medications. Manufacturers in the Viral Vector and Plasmid DNA manufacturing market are increasing the strategic business expansion activities through merger and acquisitions to increase their customer base and enhance the product portfolio which supports the growth of the target market. For instance, In 2019 Aldevron a US based company entered into a long term agreement with Sarepta Therapeutics, Inc., a leader in precision genetic medicine for rare diseases. In this agreement, Aldevron will supply plasmid DNA to fulfill Sarepta's needs for its gene therapy clinical trials and commercial supply. According to an article published by Human Gene Therapy, the acceptance of gene therapy for severe disorders, such as Alzheimer Disease, is high as compared to less severe disease, such as attention deficit hyperactivity disorder. Factors, such as technological advancements to mitigate challenges posed by conventional methods of vector production, increase in the number of clinical studies, and a growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, are primarily driving the demand for viral vector and plasmid DNA manufacturing market. However, high costs associated with gene therapies is slated to impede the growth of the viral vector and plasmid DNA manufacturing market. Conversely, the surge of the personalized medicine industry is anticipated to provide stellar growth opportunities to the viral vector and plasmid DNA manufacturing market.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC])@ https://www.reportsanddata.com/sample-enquiry-form/1938

The report provides comprehensive assessment of the market covering key elements such as revenue estimations, cost analysis, import/export, production and consumption trends, CAGR, gross margin, and supply & demand patterns. It also sheds light on recent technological developments, product advancements, and research and development activities in the region.

The report examines the key players operating in the market along with their market position, market share, revenue, gross margin, and business strategies. SWOT analysis and Porter's Five Forces Analysis are used to examine and assess the market and its players. It also covers recent mergers and acquisitions, joint ventures, collaborations, agreements, partnerships, and product launches and brand promotions.

Key companies profiled in the report include:

FUJIFILM Diosynth Biotechnologies, Kaneka Eurogentec S.A, Fin vector, Spark therapeutics, Cobra biologics, Cell and gene therapy catapult, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd, Thermo Fisher Scientific, Inc, 4D Molecular Therapeutics

Market Segmentation by Types:

By Product (Revenue, USD Million; 2018-2028)

Plasmid DNA
Viral Vectors
Non-viral Vectors
By Workflow (Revenue, USD Million, 2018 - 2028)

Upstream Processing
Vector Amplification & Expansion
Vector Recovery/Harvesting
Downstream Processing
Purification
Fill-finish
By Disease (Revenue, USD Million; 2018-2028)

Cancer
Inherited Disorders
Viral Infections
Others
By Application (Revenue, USD Million, 2018-2028)

Antisense, RNAi, & Molecular Therapy
Vaccinology
By Sales channel (Revenue, USD Million; 2018-2028)

Channel sales
Direct Sales
By End user: (Revenue, USD Million; 2018-2028)

Pharmaceutical and Biopharmaceutical Companies
Research Institutes
Order this Report @ https://www.reportsanddata.com/report-pricing/1938

Regional analysis covers in-depth analysis of analysis of the revenue, market share, and growth rate of the global Viral Vector and Plasmid DNA Manufacturing market in each region for the forecast period of 2021-2028. The report covers production and consumption rate, current and emerging trends, import/export, supply and demand, and presence of key players in each region.

North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
Italy
France
BENELUX
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
U.A.E.
South Africa
Rest of MEA
Key findings from the report suggest

Increasing acceptance of viral vector-based advanced treatments is likely to drive the segment in viral vector and plasmid DNA manufacturing market. The significant share is due to the use of adeno associated virus, lentivirus, and others.
By application, cancer is expected to account for the largest share of the market, followed by genetic disorder segment, which occupied a market share of around 33.3% in 2017.
The following are the significant genetically modified therapies rigorously studied and analyzed, namely, LUXTURNA, YESCARTA, Kymriah, INVOSSA, Zalmoxis, Strimvelis, Imlygic, Neovasculagen, Rexin-G, Oncorine, and Gendicine. Amongst these, YESCARTA and Kymriah are T-cell based gene therapies that were recently approved by the FDA, in October 2017 and August 2017, respectively. Besides, over 430 gene therapy candidates are presently in different stages of clinical development, for which over 500 clinical studies are currently underway in various regions across the globe.
The growing number of gene therapy candidates, coupled with their rapid progression through multiple phases of clinical development, is expected to continue to create an increasing demand for vectors.
North America dominates the global viral vector and plasmid DNA manufacturing market due to a large patient pool, and high acceptance of advanced treatments in the region. The region is estimated to maintain its dominance during the forecast period. Moreover, rising healthcare expenditure, availability of approved gene therapy treatments, and increasing investments are key factors that are anticipated to boost the viral vector and plasmid DNA manufacturing market in the next few years.
The viral vector and plasmid DNA manufacturing market in the Asia Pacific is projected to expand at a notable CAGR due to increasing awareness regarding viral vector-based products in developing countries and rising research initiatives in countries such as Japan and China.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1938

Thank you for reading our report. For further inquiry, please connect with us and our team will make sure the report is customized according to your requirements.

Contact Us:

John W

Head of Business Development

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

This release was published on openPR.